Patent details

Basic Information

Publication number:

EP3342428

PCT Application Number:

JP2016074464

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP168392595

PCT Publication Number:

WO2017033912

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

ANTI-CANCER AGENT COMPRISING HVJ-E AND CXCL2

French Title of Invention:

AGENT ANTICANCÉREUX COMPRENANT LA HVJ-E ET LE CXCL2

German Title of Invention:

ANTIKREBSMITTEL MIT HVJ-E UND CXCL2

SPC Number:

Dates

Filing date:

23/08/2016

Grant date:

14/10/2020

EP Publication Date:

04/07/2018

PCT Publication Date:

02/03/2017

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

14/10/2020

EP B1 Publication Date:

14/10/2020

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

23/08/2021

Expiration date:

23/08/2036

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

07/10/2020

 

 

Name:

GenomIdea Inc.

Address:

3-15, Edobori 1-chome, Nishi-ku, Osaka 550-0002, Japan (JP)

Name:

Osaka University

Address:

1-1 Yamadaoka, Suita-shi, Osaka 565-0871, Japan (JP)

Inventor

1

Name:

NAKAJIMA, Toshihiro

Address:

Japan (JP)

2

Name:

KANEDA, Yasufumi

Address:

Japan (JP)

Priority

Priority Number:

2015164600

Priority Date:

24/08/2015

Priority Country:

Japan (JP)

Classification

IPC classification:

A61K 38/19; A61P 35/00; A61K 35/76;

Publication

European Patent Bulletin

Issue number:

202042

Publication date:

14/10/2020

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages